United States · Platforms & data · MarketBeat

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Published by MarketBeat · United States 1 h ago

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

Anthropic's Revenue Surged to $16.3 Billion in the First Half of 2026, Up From $1.1 Billion a Year Ago

Seeking Alpha

SpaceX’s 80,000 Cell Site Push A Win For AST SpaceMobile, Ericsson, Nokia, NextNav, Among Others, Says Roth Capital

Morningstar

The Ensign Group, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Share

Also worth reading

Anthropic's Revenue Surged to $16.3 Billion in the First Half of 2026, Up From $1.1 Billion a Year Ago

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Saudi Arabia intercepts Houthi missile as Trump threatens new strikes

Hooters closes 35-year-old location after shutting 55 restaurants

SpaceX’s 80,000 Cell Site Push A Win For AST SpaceMobile, Ericsson, Nokia, NextNav, Among Others, Says Roth Capital

The Ensign Group, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline